Interleukin-22 from bench to bedside:a promising drug for epithelial repair  

作　　者：Bin Gao Xiaogang Xiang 

机构地区：[1]Laboratory of Liver Diseases,National Institute on Alcohol Abuse and Alcoholism,National Institutes of Health,Bethesda,MD 20892,USA

出　　处：《Cellular & Molecular Immunology》2019年第7期666-667,共2页中国免疫学杂志（英文版）

基　　金：the intramural program of the NIAAA and NIH(B.G.).

摘　　要：Cellular and Molecular Immunology(CMI),the official journal of theChinese Society of Immunology,was established in 2004.CMI hasnow become one of the leading international journals in the fieldand publishes high-quality original articles and reviews.The veryfirst research article published in the inaugural issue of CMI wasfrom our group and described,for the first time,the protectiveeffect of interleukin-22(IL-22)on the epithelium in the liver.1Fascinatingly,14 years later,the first-in-human phase I clinicalstudy of human IL-22-Fc dimer(F-652)in healthy subjects is alsopublished in CMI.2 We are very excited to see these interestingstudies of IL-22 from bench to bedside published in CMI alongsideits strong growth as a journal over the last 14 years.

关 键 词：IMMUNOLOGY protective INTERLEUKIN 

分 类 号：R57[医药卫生—消化系统]